Advances in the understanding of the hepatitis C virus (HCV) life cycle have led to the development of many promising direct-acting antiviral agents (DAA) in the last decade. An editorial in the December issue of Gastroenterology looks at the development of DAAs directed at multiple targets in the HCV life cycle and asks, “Are we ready for interferon-free treatment regimens?” Dr. Kuemmerle speaks to editorial co-author Dr. Anna S. Lok of the University of Michigan Health System; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.